European journal of clinical investigation
-
Eur. J. Clin. Invest. · Mar 2003
Randomized Controlled Trial Multicenter Study Clinical TrialTopical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial.
The treatment of distal ulcerative colitis, refractory to conventional 5-ASA/steroid treatment, is still a matter of debate. The present study aimed at confirming, with adequate statistical power, previous data indicating the usefulness of topical butyrate and 5-ASA in the treatment of this condition. ⋯ The combined treatment with topical butyrate and 5-ASA is significantly more effective than 5-ASA alone in the management of refractory distal colitis. Further improvements in the treatment of refractory distal ulcerative colitis may be feasible based on the identification of patient subgroups and the association of two or more active drugs. Butyrate may well be one of them.
-
Eur. J. Clin. Invest. · Mar 2003
Time to progression is dependent on the expression of the tumour suppressor PTEN in ovarian cancer patients.
Quantitative analyses of PTEN expression of ovarian cancer tissues were performed in this study. PTEN expression was investigated in terms of each patient's progression-free interval to indicate the role of PTEN in the generation of platinum refractory tumours. ⋯ The data suggest that decreased PTEN expression accompanies the progression of ovarian cancer. Declining PTEN expression results in a shortened relapse-free interval, whereas an increase of PTEN prolongs the time to progression. However, as far as recurrence occurs, PTEN is not the only mechanism to suppress tumour progression in ovarian cancer.